1095 related articles for article (PubMed ID: 18071030)
1. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
[TBL] [Abstract][Full Text] [Related]
2. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[TBL] [Abstract][Full Text] [Related]
3. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
Cohen JA; Imrey PB; Calabresi PA; Edwards KR; Eickenhorst T; Felton WL; Fisher E; Fox RJ; Goodman AD; Hara-Cleaver C; Hutton GJ; Mandell BF; Scott TF; Zhang H; Apperson-Hansen C; Beck GJ; Houghtaling PL; Karafa MT; Stadtler M;
Neurology; 2009 Feb; 72(6):535-41. PubMed ID: 19204263
[TBL] [Abstract][Full Text] [Related]
4. Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data.
Cohen JA; Calabresi PA; Chakraborty S; Edwards KR; Eickenhorst T; Felton WL; Fisher E; Fox RJ; Goodman AD; Hara-Cleaver C; Hutton GJ; Imrey PB; Ivancic DM; Mandell BF; Perryman JE; Scott TF; Skaramagas TT; Zhang H;
Mult Scler; 2008 Apr; 14(3):370-82. PubMed ID: 18208877
[TBL] [Abstract][Full Text] [Related]
5. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy.
Lanzillo R; Orefice G; Quarantelli M; Rinaldi C; Prinster A; Ventrella G; Spitaleri D; Lus G; Vacca G; Carotenuto B; Salvatore E; Brunetti A; Tedeschi G; Brescia Morra V
Mult Scler; 2010 Apr; 16(4):450-4. PubMed ID: 20150398
[TBL] [Abstract][Full Text] [Related]
6. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
Boz C; Ozmenoglu M; Velioglu S; Kilinc K; Orem A; Alioglu Z; Altunayoglu V
Clin Neurol Neurosurg; 2006 Feb; 108(2):124-8. PubMed ID: 16412833
[TBL] [Abstract][Full Text] [Related]
8. Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study.
Bermel RA; Weinstock-Guttman B; Bourdette D; Foulds P; You X; Rudick RA
Mult Scler; 2010 May; 16(5):588-96. PubMed ID: 20167591
[TBL] [Abstract][Full Text] [Related]
9. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
Havrdova E; Zivadinov R; Krasensky J; Dwyer MG; Novakova I; Dolezal O; Ticha V; Dusek L; Houzvickova E; Cox JL; Bergsland N; Hussein S; Svobodnik A; Seidl Z; Vaneckova M; Horakova D
Mult Scler; 2009 Aug; 15(8):965-76. PubMed ID: 19465443
[TBL] [Abstract][Full Text] [Related]
10. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
[TBL] [Abstract][Full Text] [Related]
11. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
Rudick RA; Stuart WH; Calabresi PA; Confavreux C; Galetta SL; Radue EW; Lublin FD; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA; Sandrock AW;
N Engl J Med; 2006 Mar; 354(9):911-23. PubMed ID: 16510745
[TBL] [Abstract][Full Text] [Related]
12. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Cohen JA; Barkhof F; Comi G; Hartung HP; Khatri BO; Montalban X; Pelletier J; Capra R; Gallo P; Izquierdo G; Tiel-Wilck K; de Vera A; Jin J; Stites T; Wu S; Aradhye S; Kappos L;
N Engl J Med; 2010 Feb; 362(5):402-15. PubMed ID: 20089954
[TBL] [Abstract][Full Text] [Related]
13. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
14. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
[TBL] [Abstract][Full Text] [Related]
15. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
Saida T; Tashiro K; Itoyama Y; Sato T; Ohashi Y; Zhao Z;
Neurology; 2005 Feb; 64(4):621-30. PubMed ID: 15728282
[TBL] [Abstract][Full Text] [Related]
16. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
[TBL] [Abstract][Full Text] [Related]
17. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
[TBL] [Abstract][Full Text] [Related]
18. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
19. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
Birnbaum G; Cree B; Altafullah I; Zinser M; Reder AT
Neurology; 2008 Oct; 71(18):1390-5. PubMed ID: 18525027
[TBL] [Abstract][Full Text] [Related]
20. Rationale and design of the prospective and retrospective observational study of Avonex and Rebif (PROOF) for the treatment of relapsing-remitting multiple sclerosis.
Murray TJ
Curr Med Res Opin; 2004 Jan; 20(1):25-30. PubMed ID: 14741068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
